Related Experiment Video
Updated: Jun 25, 2026

A Rat Model of Ventricular Fibrillation and Resuscitation by Conventional Closed-chest Technique
Published on: April 26, 2015
Resuscitation in paediatric septic shock using vitamin C and hydrocortisone (RESPOND): The RESPOND randomised
Kristen S Gibbons1, Sainath Raman1,2, Lalitha Av3
1Children's Intensive Care Research Program, Child Health Research Centre, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
Insights
The Resuscitation in Paediatric Septic Shock using Vitamin C and Hydrocortisone (RESPOND) trial investigates if hydrocortisone with or without vitamin C improves outcomes for critically ill children. This study presents the statistical analysis plan for this important pediatric septic shock research.
Area of Science:
- Pediatric Critical Care Medicine
- Clinical Trials Methodology
- Septic Shock Pathophysiology
Background:
- Pediatric septic shock is a life-threatening condition requiring intensive management.
- Current treatments aim to improve hemodynamics and organ function.
- The role of hydrocortisone and vitamin C in pediatric septic shock requires further investigation.
Purpose of the Study:
- To present the prespecified statistical analysis plan (SAP) for the Resuscitation in Paediatric Septic Shock using Vitamin C and Hydrocortisone (RESPOND) trial.
- To outline the methodology for analyzing the primary and secondary outcomes before data locking.
- To ensure transparency and verifiability of the trial's statistical approach.
Main Methods:
- A multicentre, three-arm, parallel group, open-label randomized controlled trial.
- Recruitment of 384 participants in pediatric intensive care units across Australia, New Zealand, India, and Brazil.
- Primary outcome: time alive and free of inotropes/vasopressors within 7 days; secondary outcomes include clinical, safety, economic, and long-term measures.
Main Results:
- The statistical analysis plan details the methods for analyzing the primary outcome using quantile regression.
- Secondary outcomes will be analyzed using appropriate statistical comparisons.
- The SAP ensures a transparent, verifiable, and predetermined analytical approach.
Conclusions:
- The RESPOND trial's SAP provides a robust framework for evaluating the efficacy of hydrocortisone with or without vitamin C in pediatric septic shock.
- The study design and analysis plan are finalized prior to recruitment completion.
- This rigorous approach will yield reliable data on treatment effectiveness and patient outcomes.
Background:
The Resuscitation in Paediatric Septic Shock using Vitamin C and Hydrocortisone (RESPOND) trial is a multicentre randomised controlled trial exploring whether the use of hydrocortisone alone, or in combination with vitamin C, increases time alive and free of vasopressors for critically ill children.
Objective:
To present the prespecified statistical analysis plan (SAP) for the RESPOND trial prior to finalising recruitment and locking the trial dataset.
Design Setting And Participants:
The RESPOND trial is a three-arm, parallel group, open-label, randomised controlled trial, recruiting in paediatric intensive care units in Australia, New Zealand, India, and Brazil. The planned sample size is 384 participants.
Main Outcome Measures:
The primary outcome is time alive and free of inotropes/vasopressors, censored at 7 days post-randomisation. Secondary outcomes include clinical (e.g. alive and free of multi-organ dysfunction, length of stay), safety, health economics (e.g. incremental costs, quality-adjusted life years), and long-term outcomes (measured at 6 months post-randomisation; e.g. health-related quality of life).
Results And Conclusions:
The SAP was designed by the Chief Investigators and approved by the RESPOND Steering Committee. Statistical analyses are summarised. The primary outcome will be analysed using quantile regression adjusted for stratification variables. Appropriate statistical comparisons between groups were planned and described in a way that is transparent, available to the public, verifiable, and predetermined before completion of data collection. The trial statistician, RESPOND Steering Committee members, and SAP authors remain blind to treatment allocation throughout the study. Data Safety and Monitoring Board members were provided with safety data with masked group identifiers during interim analyses. The RESPOND trial commenced recruitment in December, 2021, and aims to complete recruitment by mid-2026.
Trial Registration:
ACTRN12621000247875.
Related Concept Videos
Cardiopulmonary Resuscitation IV: Pharmacological Management
Cardiopulmonary Resuscitation I: Adult
Acute Coronary Syndrome V: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Pharmaceutical Poisoning: Treatment Strategies